A novel target gene, SKP2, within the 5p13 amplicon that is frequently detected in small cell lung cancers

被引:126
作者
Yokoi, S
Yasui, K
Saito-Ohara, F
Koshikawa, K
Iizasa, T
Fujisawa, T
Terasaki, T
Horii, A
Takahashi, T
Hirohashi, S
Inazawa, J [1 ]
机构
[1] Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Bunkyo Ku, Tokyo 1138519, Japan
[2] Chiba Univ, Grad Sch Med, Dept Thorac Surg, Chiba, Japan
[3] Aichi Canc Ctr, Res Inst, Div Mol Oncol, Nagoya, Aichi 464, Japan
[4] Aichi Canc Ctr, Res Inst, Div Immunol, Nagoya, Aichi 464, Japan
[5] Natl Canc Ctr, Res Inst, Div Pathol, Tokyo 104, Japan
[6] Tohoku Univ, Grad Sch Med, Dept Mol Pathol, Sendai, Miyagi 980, Japan
关键词
D O I
10.1016/S0002-9440(10)64172-7
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
We investigated DNA copy-number aberrations in 22 cell lines derived from small cell lung cancers (SCLCs) using comparative genomic hybridization. A minimal common region at 5p13, within the 5p11-p13 amplicon that was most frequently involved, harbored the CDH6, PC4, and SKP2 genes. These three genes showed amplification and consequent overexpression in the SCLC cell lines. SKP2 positively regulates progression of cell cycle by targeting several regulators, such as the cell-cycle inhibitor p27(KIP1), for ubiquitin-mediated degradation. SKP2 was amplified in 7 (44%) of 16 primary SCLC tumors, and consequently overexpressed in 10 (83%) of the 12 of those tumors we examined. Expression levels of SKP2 protein were cell cycle-dependent in SCLC cells as well as in normal cells, and were correlated with the DNA copy-number of the gene. There was an inverse correlation between the expression of SKP2 and p27(KIP1) proteins. Downregulation of SKP2 using an anti-sense oligonucleotide remarkably suppressed the growth of SCLC cells. Our results indicate that SKP2 is likely to be a target of the 5p13 amplification and to play an important role in the growth of SCLC cells.
引用
收藏
页码:207 / 216
页数:10
相关论文
共 67 条
[41]   Comparative genomic hybridization and chromosomal instability in solid tumours [J].
Rooney, PH ;
Murray, GI ;
Stevenson, DAJ ;
Haites, NE ;
Cassidy, J ;
McLeod, HL .
BRITISH JOURNAL OF CANCER, 1999, 80 (5-6) :862-873
[42]  
Sakabe T, 1999, CANCER RES, V59, P511
[43]  
Schwendel A, 1997, INT J CANCER, V74, P86, DOI 10.1002/(SICI)1097-0215(19970220)74:1<86::AID-IJC15>3.0.CO
[44]  
2-G
[45]   BIOLOGICAL, PATHOLOGICAL AND CLINICAL-FEATURES OF SMALL-CELL LUNG-CANCER [J].
SHIMOSATO, Y ;
NAKAJIMA, T ;
HIROHASHI, S ;
MORINAGA, S ;
TERASAKI, T ;
YAMAGUCHI, K ;
SAIJO, N ;
SUEMASU, K .
CANCER LETTERS, 1986, 33 (03) :241-258
[46]  
SHIMOYAMA Y, 1995, CANCER RES, V55, P2206
[47]  
Shinomiya T, 1999, GENE CHROMOSOME CANC, V24, P337, DOI 10.1002/(SICI)1098-2264(199904)24:4<337::AID-GCC7>3.0.CO
[48]  
2-O
[49]   p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells [J].
Sutterlüty, H ;
Chatelain, E ;
Marti, A ;
Wirbelauer, C ;
Senften, M ;
Müller, U ;
Krek, W .
NATURE CELL BIOLOGY, 1999, 1 (04) :207-214
[50]  
SUYAMA M, 1984, IGAKU NO AYUMI, V131, P161